XPOF Q3 Revenue Falls 21% to $62.3M; Studio-Openings Outlook Cut, EBITDA Guidance Narrowed
XPOF is trading near its 52-week low of $3.565 (14% above the low).
Summary
Xponential reported Q3 revenue of $62.3 million, down 21%, and Adjusted EBITDA of $24.3 million, down 27%, while cutting its 2026 studio-opening outlook and narrowing EBITDA guidance. The board's strategic alternatives review, including a possible sale, remains active.
Key Events · Earnings and Guidance · XPOF
-
Q3 Revenue Down 21%
Total revenue was $62.3 million versus $78.8 million a year earlier, with franchise revenue down 16% to $43.4 million and equipment revenue down 42% to $4.3 million.
-
Profit Shrinks, GAAP Turns Positive
Adjusted EBITDA fell 27% to $24.3 million from $33.5 million, and adjusted net income was $2.2 million, or $0.04 per basic share, versus $19.3 million, or $0.36. GAAP net income was $4.9 million, or $0.10 per basic share, against a $6.7 million loss a year ago.
-
Studio Growth Outlook Cut
Full-year 2026 net new studio openings are now guided to 124-130, a 37% decline at the midpoint, versus prior guidance of approximately 150. Adjusted EBITDA guidance narrowed to $91.0-94.0 million from $91.0-97.0 million.
-
Leverage and Cash Burn
The company held $27.2 million of cash, cash equivalents and restricted cash against $521.1 million of total long-term debt, and used $21.1 million of cash in operating activities over the first nine months of 2026.
Analysis · XPOF · Trade & Services
The profit base is shrinking even as the top line contracts: revenue dropped 21% to $62.3 million and Adjusted EBITDA fell 27% to $24.3 million. Management cut its full-year net new studio openings to 124-130 from roughly 150 and narrowed Adjusted EBITDA to $91.0-94.0 million from $91.0-97.0 million, signaling to franchisees and investors that unit growth is slowing, not just revenue per unit. The balance sheet is the pressure point: $27.2 million of cash against $521.1 million of long-term debt, with $21.1 million of cash burned in the first nine months. Against that backdrop, the board's strategic alternatives review, run with Jefferies and explicitly including a possible sale or merger, is the live variable — and it sits alongside activist Fund 1 Investments' non-binding $5.61-$7.00 per share take-private proposal from October 30 and the 19.9% poison pill adopted October 13.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XPOF was trading at $4.05 on NYSE in the Trade & Services sector, with a market capitalization of approximately $217.7M. The 52-week trading range was $3.57 to $9.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.